NCT04414852

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

A Multi-center, Non-randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetics of Apatinib Mesylate in Subjects With Impaired Renal Function and Healthy Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The primary objective of the study is to compare the pharmacokinetics of apatinib in subjects with impaired renal function and healthy subjects, to give dose recommendations for patients with impaired renal function.

Conditions

• Subjects With Impaired Renal Function and Healthy Subjects

Interventions

Type	Name	Description
DRUG	Apatinib Mesylate	All the subjects will be administrated with 250mg apatinib on day 1

Timeline

• Start date: 2020-06-05
• Primary completion: 2021-01-15
• Completion: 2021-04-30
• First posted: 2020-06-04
• Last updated: 2020-06-04